More Neurizon Therapeutics Limited news
Neurizon Therapeutics LimitedASX: NUZ

Appendix 4C - Quarterly Report & Brief Company Update

Oct 26, 2017 at 7:18 AM EDT · Issued by Neurizon Therapeutics Limited

Filed with ASX · Oct 26, 2017 at 7:18 AM EDT · 9 pages · English

On 6ix: 6ix.com/news/appendix-4c-quarterly-report-and-brief-company-update

Neurizon Therapeutics Limited on 6ix

Story so far

  • Appendix 4C - Quarterly Report & Company Update - March 2017Apr 13, 2017
  • Appendix 4C - Quarterly Report & Company UpdateJan 31, 2017
  • Appendix 4C Quarterly & Brief Company Update - June 2016Jul 29, 2016

Earlier from Neurizon Therapeutics

  • Monepantel reformulation project continues to progressOct 16, 2017
  • New patent secured in US for non-cancer applicationsOct 9, 2017
  • Reformulation project achieves first milestones and on-trackSep 19, 2017
  • PharmAust secures core Europe patentSep 11, 2017
  • PharmAust & Nihon Nohyaku Japan Enter Assignment AgreementSep 3, 2017

Later from Neurizon Therapeutics

  • Epichem Update - progress on milestones and revenue targetsOct 31, 2017
  • New drugs patented for cancer in USANov 15, 2017
  • New MPL analogues show greater anti-cancer activityNov 22, 2017
  • PharmAust Raises $1.873m via an Oversubscribed PlacementDec 5, 2017
  • Phase II Dog Lymphoma Trial Confirms MPL Clinical BenefitDec 12, 2017
All Neurizon Therapeutics news releases↗

Follow Neurizon Therapeutics into a list and get an email when it puts out news.

Follow Neurizon Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer